RAINMED-B Reports Interim Results with Net Loss Narrowing 31.65% Year-on-Year

Stock News08-31

RAINMED-B (02297) has released its interim results for the six months ended June 30, 2026. During the period, the group recorded revenue of RMB 14.672 million, a year-on-year increase of 41.01%. The loss attributable to shareholders of the company narrowed to RMB 21.989 million, a reduction of 31.65% compared to the same period last year. Basic loss per share stood at RMB 0.02.

According to the announcement, the revenue growth was primarily driven by increased sales of the FlashPressure caFFR pressure sensor. Additionally, the group's coronary cutting balloon, designated as a volume-based procurement (VBP) product, began generating sales revenue of approximately RMB 1.39 million during the reporting period. With the continued rollout of the centralized procurement policy and the gradual expansion of hospital coverage, sales volume for this product is expected to grow steadily.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment